Michael Dabrowski

Overview

Michael Dabrowski is an angel investor and entrepreneur with a focus on early-stage biotechnology companies. He co-founded Synthego, a company that provides gene-editing tools to accelerate the development of genomic medicines. Under his leadership, Synthego has become a significant player in the biotechnology sector, offering products that enable researchers to develop gene-edited products efficiently. His investment strategy centers on supporting innovative companies in the biotechnology and healthcare sectors, particularly those in the seed and early stages. Dabrowski's approach emphasizes the potential of emerging technologies to revolutionize healthcare and improve patient outcomes. He seeks to invest in companies that are developing groundbreaking solutions in genetic medicine and related fields. Dabrowski's track record includes investments in companies like Autocode and Plethora, reflecting his commitment to fostering innovation in the biotechnology space. His experience as a founder and investor provides him with a unique perspective on the challenges and opportunities in the industry, enabling him to offer valuable guidance and support to the companies he invests in.

Investment Focus

• Innovative biotechnology solutions
• Strong founding team
• Scalable business model

Portfolio Companies